A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8+ T cells

To investigate the in vivo effect of the fusion protein and its subcomponents on T cell function, CD8 T cells of the indicated treament were isolated from tumor, spleen and lympho nodes (LN) for T cell receptor sequencing assay. Total RNAs were extracted form CD8 T cells form tumor, spleen and LN, follwed by constructing RNA sequencing libraries with the same amount RNA (100ng, RIN >8) using QIAseq mouse TCR Sequencing kit (#333705) TCR libraries were sequenced using an Illumina NextSeq 550 system for CDR3 region. The TCR repertoire analysis were processed by QIAseq Immune Repertoire RNA Library Kit Data Analysis Portal. Each sequencing sampele was mixed sample from same treatment (N=3); Total 12 samples from 4 treatment groups and 3 different tissues